A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Docosahexaenoic acid (Primary) ; Soya oil emulsion
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms SCOT
- Sponsors Sancilio & Company
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
- 03 Oct 2017 Status changed from active, no longer recruiting to completed, according to a Sancilio Pharmaceuticals media release.
- 26 Jul 2017 Top-line results from the study are expected in early Q4 this year, according to a Sancilio Pharmaceuticals media release.